Published in Retrovirology on January 30, 2007
HIV-associated chronic immune activation. Immunol Rev (2013) 1.38
The molecular basis of chloroquine block of the inward rectifier Kir2.1 channel. Proc Natl Acad Sci U S A (2008) 1.30
Raltegravir is a potent inhibitor of XMRV, a virus implicated in prostate cancer and chronic fatigue syndrome. PLoS One (2010) 1.27
Chloroquine mediated molecular tuning of astrocytes for enhanced permissiveness to HIV infection. Virology (2008) 0.98
Immune Suppression by Myeloid Cells in HIV Infection: New Targets for Immunotherapy. Open AIDS J (2014) 0.83
Transient increase of interferon-stimulated genes and no clinical benefit by chloroquine treatment during acute simian immunodeficiency virus infection of macaques. AIDS Res Hum Retroviruses (2013) 0.80
BCA2/Rabring7 targets HIV-1 Gag for lysosomal degradation in a tetherin-independent manner. PLoS Pathog (2014) 0.80
Chloroquine and beyond: exploring anti-rheumatic drugs to reduce immune hyperactivation in HIV/AIDS. Retrovirology (2015) 0.80
Chronic use of chloroquine disrupts the urine concentration mechanism by lowering cAMP levels in the inner medulla. Am J Physiol Renal Physiol (2012) 0.78
Role of anti-inflammatory compounds in human immunodeficiency virus-1 glycoprotein120-mediated brain inflammation. J Neuroinflammation (2014) 0.78
Immune activation and the role of TLRs and TLR agonists in the pathogenesis of HIV-1 infection in the humanized mouse model. J Infect Dis (2013) 0.78
Development of polyether urethane intravaginal rings for the sustained delivery of hydroxychloroquine. Drug Des Devel Ther (2014) 0.77
Targeting endosomal acidification by chloroquine analogs as a promising strategy for the treatment of emerging viral diseases. Pharmacol Res Perspect (2017) 0.75
Antiviral, antifungal, and antiparasitic activities of fluoroquinolones optimized for treatment of bacterial infections: a puzzling paradox or a logical consequence of their mode of action? Eur J Clin Microbiol Infect Dis (2014) 0.75
Rapid and simple method for purification of nucleic acids. J Clin Microbiol (1990) 44.73
MEGA: Molecular Evolutionary Genetics Analysis software for microcomputers. Comput Appl Biosci (1994) 28.25
Antibody neutralization and escape by HIV-1. Nature (2003) 21.48
Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. J Infect Dis (2005) 21.08
DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells. Cell (2000) 14.43
Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda. Lancet (2001) 13.32
Identification of DC-SIGN, a novel dendritic cell-specific ICAM-3 receptor that supports primary immune responses. Cell (2000) 8.34
The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120. J Virol (2002) 6.11
Dendritic cells exposed to human immunodeficiency virus type-1 transmit a vigorous cytopathic infection to CD4+ T cells. Science (1992) 5.61
Simian immunodeficiency virus rapidly penetrates the cervicovaginal mucosa after intravaginal inoculation and infects intraepithelial dendritic cells. J Virol (2000) 4.87
Diversity of receptors binding HIV on dendritic cell subsets. Nat Immunol (2002) 4.63
The C-type lectin superfamily in the immune system. Immunol Rev (1998) 3.63
Cytoplasmic vacuolation of mouse peritoneal macrophages and the uptake into lysosomes of weakly basic substances. J Cell Biol (1981) 3.56
DC-SIGN interactions with human immunodeficiency virus type 1 and 2 and simian immunodeficiency virus. J Virol (2001) 2.95
Structure-based, targeted deglycosylation of HIV-1 gp120 and effects on neutralization sensitivity and antibody recognition. Virology (2003) 2.25
N-linked glycosylation of the HIV type-1 gp120 envelope glycoprotein as a major determinant of CCR5 and CXCR4 coreceptor utilization. J Biol Chem (2001) 2.07
Low levels of HIV-1 infection in cutaneous dendritic cells promote extensive viral replication upon binding to memory CD4+ T cells. J Exp Med (1995) 2.05
HIV-1 selection by epidermal dendritic cells during transmission across human skin. J Exp Med (1998) 2.02
Productive infection of dendritic cells by HIV-1 and their ability to capture virus are mediated through separate pathways. J Clin Invest (1997) 1.98
Role of protein N-glycosylation in pathogenesis of human immunodeficiency virus type 1. Proc Natl Acad Sci U S A (1988) 1.86
Inhibition of human immunodeficiency virus infectivity by chloroquine. AIDS Res Hum Retroviruses (1990) 1.34
Lewis X component in human milk binds DC-SIGN and inhibits HIV-1 transfer to CD4+ T lymphocytes. J Clin Invest (2005) 1.34
DC-SIGN on B lymphocytes is required for transmission of HIV-1 to T lymphocytes. PLoS Pathog (2006) 1.25
Hydroxychloroquine treatment of patients with human immunodeficiency virus type 1. Clin Ther (1996) 1.21
Anti-HIV effects of chloroquine: inhibition of viral particle glycosylation and synergism with protease inhibitors. J Acquir Immune Defic Syndr (2004) 1.21
Anti-HIV effects of chloroquine: mechanisms of inhibition and spectrum of activity. AIDS (2001) 1.19
HIV: The deadly passenger in dendritic cells. Curr Biol (1999) 1.11
Inhibition of HIV Env binding to cellular receptors by monoclonal antibody 2G12 as probed by Fc-tagged gp120. Retrovirology (2006) 1.08
Comparison of hydroxychloroquine with zidovudine in asymptomatic patients infected with human immunodeficiency virus type 1. Clin Ther (1997) 1.06
Selective regulation of cytokine secretion by hydroxychloroquine: inhibition of interleukin 1 alpha (IL-1-alpha) and IL-6 in human monocytes and T cells. J Rheumatol (1993) 1.04
The anti-HIV-1 activity of chloroquine. J Clin Virol (2001) 1.03
Inhibition of HIV-1 replication by hydroxychloroquine: mechanism of action and comparison with zidovudine. Clin Ther (1997) 1.03
The role of Langerhans cells in the sexual transmission of HIV. J Dermatol Sci (2005) 1.00
Capture and transfer of simian immunodeficiency virus by macaque dendritic cells is enhanced by DC-SIGN. J Virol (2002) 0.94
Potency of HIV-1 envelope glycoprotein gp120 antibodies to inhibit the interaction of DC-SIGN with HIV-1 gp120. Virology (2004) 0.86
Chloroquine inhibits HIV-1 replication in human peripheral blood lymphocytes. Immunol Lett (1998) 0.85
Inhibition of HIV-1 Tat-mediated transactivation by quinacrine and chloroquine. Biochem Biophys Res Commun (1996) 0.84
Preferential infection and depletion of Mycobacterium tuberculosis-specific CD4 T cells after HIV-1 infection. J Exp Med (2010) 2.07
Identification of sequential viral escape mutants associated with altered T-cell responses in a human immunodeficiency virus type 1-infected individual. J Virol (2003) 1.57
Lewis X component in human milk binds DC-SIGN and inhibits HIV-1 transfer to CD4+ T lymphocytes. J Clin Invest (2005) 1.34
Efficient capture of antibody neutralized HIV-1 by cells expressing DC-SIGN and transfer to CD4+ T lymphocytes. J Immunol (2007) 1.21
Broad cross-clade T-cell responses to gag in individuals infected with human immunodeficiency virus type 1 non-B clades (A to G): importance of HLA anchor residue conservation. J Virol (2005) 1.15
Use of dried spots of whole blood, plasma, and mother's milk collected on filter paper for measurement of human immunodeficiency virus type 1 burden. J Clin Microbiol (2007) 1.15
Phenotypic and genotypic comparisons of CCR5- and CXCR4-tropic human immunodeficiency virus type 1 biological clones isolated from subtype C-infected individuals. J Virol (2004) 1.13
Optimization of human immunodeficiency virus type 1 envelope glycoproteins with V1/V2 deleted, using virus evolution. J Virol (2008) 1.10
Sexual transmission of hepatitis C virus in human immunodeficiency virus-negative men who have sex with men: a series of case reports. Sex Transm Dis (2011) 1.10
The carbohydrate at asparagine 386 on HIV-1 gp120 is not essential for protein folding and function but is involved in immune evasion. Retrovirology (2008) 1.10
Bile salt-stimulated lipase from human milk binds DC-SIGN and inhibits human immunodeficiency virus type 1 transfer to CD4+ T cells. Antimicrob Agents Chemother (2006) 1.06
Only five of 10 strictly conserved disulfide bonds are essential for folding and eight for function of the HIV-1 envelope glycoprotein. Mol Biol Cell (2008) 1.01
HIV RNA levels in transmission sources only weakly predict plasma viral load in recipients. AIDS (2010) 1.01
Mucin 6 in seminal plasma binds DC-SIGN and potently blocks dendritic cell mediated transfer of HIV-1 to CD4(+) T-lymphocytes. Virology (2009) 1.01
CTL escape and increased viremia irrespective of HIV-specific CD4+ T-helper responses in two HIV-infected individuals. Virology (2005) 0.95
Altered dynamics and differential infection profiles of lymphoid and myeloid cell subsets during acute and chronic HIV-1 infection. J Leukoc Biol (2011) 0.94
Rapid CD4+ T-lymphocyte depletion in rhesus monkeys infected with a simian-human immunodeficiency virus expressing the envelope glycoproteins of a primary dual-tropic Ethiopian Clade C HIV type 1 isolate. AIDS Res Hum Retroviruses (2004) 0.92
Primary HIV-1 subtype C infection in Ethiopia. J Acquir Immune Defic Syndr (2002) 0.92
The HIV type 1 epidemic in Belarus: predominance of Eastern European subtype A strains and circulation of subtype B viruses. AIDS Res Hum Retroviruses (2005) 0.90
Dendritic cell-induced activation of latent HIV-1 provirus in actively proliferating primary T lymphocytes. PLoS Pathog (2013) 0.90
Lack of in vivo compartmentalization among HIV-1 infected naïve and memory CD4+ T cell subsets. Virology (2009) 0.90
Dendritic cells preferentially transfer CXCR4-using human immunodeficiency virus type 1 variants to CD4+ T lymphocytes in trans. J Virol (2008) 0.89
Development of a nucleic acid sequence-based amplification assay that uses gag-based molecular beacons to distinguish between human immunodeficiency virus type 1 subtype C and C' infections in Ethiopia. J Clin Microbiol (2004) 0.87
Selective packaging of cellular miRNAs in HIV-1 particles. Virus Res (2012) 0.86
Binding of human milk to pathogen receptor DC-SIGN varies with bile salt-stimulated lipase (BSSL) gene polymorphism. PLoS One (2011) 0.86
Statins disrupt CCR5 and RANTES expression levels in CD4(+) T lymphocytes in vitro and preferentially decrease infection of R5 versus X4 HIV-1. PLoS One (2007) 0.85
Characterization of an HIV-1 group M variant that is distinct from the known subtypes. AIDS Res Hum Retroviruses (2007) 0.84
Latency profiles of full length HIV-1 molecular clone variants with a subtype specific promoter. Retrovirology (2011) 0.84
Differences in HIV type 1 RNA plasma load profile of closely related cocirculating Ethiopian subtype C strains: C and C'. AIDS Res Hum Retroviruses (2010) 0.83
Use of (alternative) coreceptors for HIV entry. Curr Opin HIV AIDS (2012) 0.83
Association between gp120 envelope V1V2 and V4V5 variable loop profiles in a defined HIV-1 transmission cluster. AIDS (2015) 0.82
Surveillance technology for HIV-1 subtype C in Ethiopia: an env-based NASBA molecular beacon assay to discriminate between subcluster C and C'. J Virol Methods (2005) 0.81
HIV-1 autologous antibody neutralization associates with mother to child transmission. PLoS One (2013) 0.81
Evidence of genetic variability of human immunodeficiency virus type 1 in plasma and cervicovaginal lavage in ethiopian women seeking care for sexually transmitted infections. AIDS Res Hum Retroviruses (2005) 0.80
HIV type 1 C and C' subclusters based on long terminal repeat sequences in the Ethiopian type 1 subtype C epidemic. AIDS Res Hum Retroviruses (2003) 0.80
HIV type 1 mother-to-child transmission facilitated by distinctive glycosylation sites in the gp120 envelope glycoprotein. AIDS Res Hum Retroviruses (2011) 0.79
Varied sensitivity to therapy of HIV-1 strains in CD4+ lymphocyte sub-populations upon ART initiation. AIDS Res Ther (2010) 0.79
HIV-1 disease progression is associated with bile-salt stimulated lipase (BSSL) gene polymorphism. PLoS One (2012) 0.79
Quantitation of HIV-1 DNA with a sensitive TaqMan assay that has broad subtype specificity. J Virol Methods (2012) 0.79
Innate immune factors associated with HIV-1 transmission. Curr Opin HIV AIDS (2011) 0.78
HIV vaccine: it may take two to tango, but no party time yet. Retrovirology (2009) 0.78
Effects of helminths and Mycobacterium tuberculosis infection on HIV-1: a cellular immunological perspective. Curr Opin HIV AIDS (2012) 0.76
HIV-1 (co)receptors: implications for vaccine and therapy design. Curr Pharm Des (2010) 0.76
RNA detection and subtype C assessment of HIV-1 in infants with diarrhea in Ethiopia. Open AIDS J (2009) 0.75
Transmission of two distinct HIV type 1 strains to an individual that were harbored for many years by another. AIDS Res Hum Retroviruses (2011) 0.75
Generation of representative primary virus isolates from blood plasma after isolation of HIV-1 with CD44 MicroBeads. Arch Virol (2010) 0.75
Increased HIV-1 activity in anal high-grade squamous intraepithelial lesions compared with unaffected anal mucosa in men who have sex with men. Clin Infect Dis (2014) 0.75
Human immunodeficiency virus type 1 gp120 envelope characteristics associated with disease progression differ in family members infected with genetically similar viruses. J Gen Virol (2012) 0.75
Generation of HIV-1 primary isolates representative of plasma variants using the U87.CD4 cell line. J Virol Methods (2010) 0.75